

# Pim J French

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2715038/publications.pdf>

Version: 2024-02-01

108  
papers

10,295  
citations

87888

38  
h-index

36028

97  
g-index

118  
all docs

118  
docs citations

118  
times ranked

12320  
citing authors

#	ARTICLE	IF	CITATIONS
1	Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 293-301.	3.9	12
2	Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning. <i>Neuro-Oncology</i> , 2023, 25, 279-289.	1.2	34
3	The <i>EGFRvIII</i> transcriptome in glioblastoma: A meta-omics analysis. <i>Neuro-Oncology</i> , 2022, 24, 429-441.	1.2	7
4	Landscape of Driver Gene Events, Biomarkers and Druggable Targets Identified by Whole Genome Sequencing of Glioblastomas. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab177.	0.7	3
5	<i>MGMT</i> promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. <i>Neuro-Oncology</i> , 2022, 24, 665-667.	1.2	5
6	Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2440-2448.	7.0	3
7	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH-wildtype: Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2527-2535.	7.0	27
8	Human branching cholangiocyte organoids recapitulate functional bile duct formation. <i>Cell Stem Cell</i> , 2022, 29, 776-794.e13.	11.1	17
9	Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2539-2545.	1.6	23
10	The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	6
11	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	27.6	826
12	Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab103.	0.7	10
13	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021, 141, 945-957.	7.7	32
14	You spin me right around. <i>Neuro-Oncology</i> , 2021, 23, 707-708.	1.2	0
15	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	12.8	47
16	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021, 23, 1547-1559.	1.2	34
17	SMARCAD1-mediated active replication fork stability maintains genome integrity. <i>Science Advances</i> , 2021, 7, .	10.3	15
18	Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. <i>Blood Advances</i> , 2021, 5, 2687-2700.	5.2	21

#	ARTICLE	IF	CITATIONS
19	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC Tj ETQq1 Oncology, The, 2021, 22, 813-823.	10.7	132
20	The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma. Data in Brief, 2021, 37, 107191.	1.0	13
21	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	7.7	34
22	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. Cancers, 2021, 13, 47.	3.7	106
23	Modeling Prostate Cancer Treatment Responses in the Organoid Era: 3D Environment Impacts Drug Testing. Biomolecules, 2021, 11, 1572.	4.0	10
24	Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer. EBioMedicine, 2021, 73, 103681.	6.1	6
25	TMOD-19. FROM PATIENT TO PETRI DISH: INCREASING PATIENT-DERIVED GLIOBLASTOMA CULTURE EFFICIENCIES TO 95%. Neuro-Oncology, 2021, 23, vi219-vi219.	1.2	0
26	Fusion transcripts and their genomic breakpoints in polyadenylated and ribosomal RNAâ€“minus RNA sequencing data. GigaScience, 2021, 10, .	6.4	10
27	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncology, 2020, 22, 515-523.	1.2	140
28	Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. Journal of Clinical Oncology, 2020, 38, 81-99.	1.6	84
29	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. Neuro-Oncology Advances, 2020, 2, vdz051.	0.7	9
30	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-Oncology, 2020, 22, 684-693.	1.2	126
31	Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma. Cancers, 2020, 12, 3589.	3.7	19
32	Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors. EBioMedicine, 2020, 56, 102796.	6.1	7
33	A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?. Cancers, 2020, 12, 3775.	3.7	9
34	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
35	Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. Scientific Reports, 2020, 10, 2927.	3.3	8
36	Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives. Cancers, 2020, 12, 751.	3.7	66

#	ARTICLE	IF	CITATIONS
37	Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz001.	0.7	9
38	Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients. <i>Journal of Neuro-Oncology</i> , 2019, 144, 79-87.	2.9	11
39	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 205-210.	2.9	24
40	Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. <i>Scientific Reports</i> , 2019, 9, 14643.	3.3	44
41	Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm. <i>Clinical Cancer Research</i> , 2019, 25, 7455-7462.	7.0	70
42	Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , 2019, 21, 1263-1272.	1.2	20
43	A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. <i>Prostate</i> , 2019, 79, 937-948.	2.3	14
44	ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION. <i>Neuro-Oncology</i> , 2019, 21, vi14-vi14.	1.2	5
45	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	27.8	320
46	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. <i>Nature</i> , 2019, 574, 707-711.	27.8	129
47	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166.	7.7	298
48	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 349-357.	2.9	24
49	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. <i>Neuro-Oncology</i> , 2018, 20, 873-884.	1.2	119
50	Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. <i>European Journal of Cancer</i> , 2018, 94, 168-178.	2.8	28
51	TRiC controls transcription resumption after UV damage by regulating Cockayne syndrome protein A. <i>Nature Communications</i> , 2018, 9, 1040.	12.8	27
52	The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. <i>Neuro-Oncology</i> , 2018, 20, 103-112.	1.2	220
53	ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi22-vi22.	1.2	0
54	TMOD-25. MODELING IDH1-MUTATED GLIOMAS: GENERATION, CHARACTERIZATION AND THERAPEUTIC SENSITIVITIES OF SEVEN PATIENT-DERIVED IDH1-MUTANT GLIOMA CELL LINES. <i>Neuro-Oncology</i> , 2018, 20, vi274-vi274.	1.2	0

#	ARTICLE	IF	CITATIONS
55	IMMU-62. LOW-GRADE GLIOMA EXCLUDE CD8 T CELLS, WHICH IS ACCOMPANIED BY LOW EXPRESSION OF CHEMO-ATTRACTANTS, NOT IMMUNOGENIC ANTIGENS. <i>Neuro-Oncology</i> , 2018, 20, vi135-vi135.	1.2	0
56	PATH-42. EGFR-AMPLIFIED IDH-WILDTYPE GLIOBLASTOMAS SELDOM TRANSFORM INTO A HYPERMUTATED PHENOTYPE. <i>Neuro-Oncology</i> , 2018, 20, vi168-vi168.	1.2	0
57	Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. <i>Acta Neuropathologica Communications</i> , 2018, 6, 126.	5.2	38
58	ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX-M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE		

#	ARTICLE	IF	CITATIONS
73	A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. <i>Molecular Oncology</i> , 2016, 10, 1296-1304.	4.6	19
74	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. <i>Cancer Research</i> , 2016, 76, 525-534.	0.9	93
75	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
76	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. <i>Neuro-Oncology</i> , 2016, 18, 388-400.	1.2	143
77	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. <i>Acta Neuropathologica Communications</i> , 2015, 3, 88.	5.2	42
78	Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. <i>Neuro-Oncology</i> , 2015, 17, 935-941.	1.2	136
79	Tumor-specific mutations in low-frequency genes affect their functional properties. <i>Journal of Neuro-Oncology</i> , 2015, 122, 461-470.	2.9	13
80	Mutation specific functions of EGFR result in a mutation-specific downstream pathway activation. <i>European Journal of Cancer</i> , 2015, 51, 893-903.	2.8	21
81	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 1943-1950.	1.6	21
82	AT-34 CONSTRUCTION OF AN INTEGRATED DIAGNOSTIC ALGORITHM CONSISTING OF CONSENSUS HISTOLOGIC AND MOLECULAR PARAMETERS OF TWO EORTC TRIALS ON ANAPLASTIC GLIOMA. <i>Neuro-Oncology</i> , 2014, 16, v16-v16.	1.2	0
83	Raman spectroscopy can discriminate distinct glioma subtypes as defined by RNA expression profiling. <i>Journal of Raman Spectroscopy</i> , 2013, 44, 1217-1221.	2.5	5
84	Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951. <i>Journal of Clinical Oncology</i> , 2013, 31, 328-336.	1.6	99
85	Molecular subtypes of glioma identified by genome-wide methylation profiling. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 665-674.	2.8	27
86	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	7.7	146
87	Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951. <i>Journal of Clinical Oncology</i> , 2013, 31, 344-350.	1.6	1,003
88	MGMT- <i>STP27</i> Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951. <i>Clinical Cancer Research</i> , 2013, 19, 5513-5522.	7.0	106
89	Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules. <i>Neuro-Oncology</i> , 2013, 15, 1684-1695.	1.2	55
90	Structural and Expression Differences Between the Vasculature of Pilocytic Astrocytomas and Glioblastomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 1171-1181.	1.7	12

#	ARTICLE	IF	CITATIONS
91	Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors. <i>Advances in Anatomic Pathology</i> , 2013, 20, 32-38.	4.3	73
92	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
93	Subgroup-specific alternative splicing in medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 485-499.	7.7	28
94	Detailed Characterization of Alterations of Chromosomes 7, 9, and 10 in Glioblastomas as Assessed by Single-Nucleotide Polymorphism Arrays. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 634-647.	2.8	55
95	Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. <i>Nature Genetics</i> , 2011, 43, 1256-1261.	21.4	488
96	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. <i>Lancet Oncology</i> , The, 2011, 12, 83-91.	10.7	188
97	Molecular Subtypes of Gliomas. , 2011, , 25-29.		0
98	Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. <i>Journal of Neuro-Oncology</i> , 2011, 103, 221-230.	2.9	21
99	IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. <i>Annals of Neurology</i> , 2011, 69, 455-463.	5.3	132
100	A Hypermethylated Phenotype Is a Better Predictor of Survival than <i>MGMT</i> Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951. <i>Clinical Cancer Research</i> , 2011, 17, 7148-7155.	7.0	107
101	Genetic Alterations in Glioma. <i>Cancers</i> , 2011, 3, 1129-1140.	3.7	24
102	Absence of Common Somatic Alterations in Genes on 1p and 19q in Oligodendrogliomas. <i>PLoS ONE</i> , 2011, 6, e22000.	2.5	13
103	Integrated genomic profiling identifies candidate genes implicated in glioma genesis and a novel <i>LEO1</i> SLC12A1 fusion gene. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 509-517.	2.8	25
104	Segregation of non-p.R132H mutations in <i>IDH1</i> in distinct molecular subtypes of glioma. <i>Human Mutation</i> , 2010, 31, E1186-E1199.	2.5	90
105	Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology. <i>Cancer Research</i> , 2009, 69, 9065-9072.	0.9	575
106	Exon Expression Arrays as a Tool to Identify New Cancer Genes. <i>PLoS ONE</i> , 2008, 3, e3007.	2.5	12
107	Identification of Differentially Regulated Splice Variants and Novel Exons in Glial Brain Tumors Using Exon Expression Arrays. <i>Cancer Research</i> , 2007, 67, 5635-5642.	0.9	81
108	Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas. <i>Cancer Research</i> , 2005, 65, 11335-11344.	0.9	102